Welcome to our dedicated page for Rigel Pharmaceuticals news (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals stock.
Rigel Pharmaceuticals Inc (NASDAQ: RIGL) is a clinical-stage biotechnology company pioneering small molecule therapies for hematologic disorders, cancer, and immune diseases. This news hub provides investors and healthcare professionals with rigorously verified updates on RIGL's clinical developments, regulatory milestones, and strategic partnerships.
Key resources include earnings announcements, trial result disclosures, FDA submissions, and licensing agreements. Our curated collection enables stakeholders to track the progress of oral kinase inhibitors and novel therapeutic candidates through development pipelines.
Bookmark this page for centralized access to Rigel's latest scientific advancements and business updates. All content is maintained to reflect current developments while preserving historical context for longitudinal analysis of the company's progress.
Rigel Pharmaceuticals (Nasdaq: RIGL) announced inducement equity awards under its Inducement Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The company granted 24,775 stock options and 16,555 restricted stock units (RSUs) to 11 non-executive employees. Awards vest over four years with a one-year cliff. Grants were approved by the Compensation Committee and issued as inducements for new hires.
Rigel (Nasdaq: RIGL) announced that Raul Rodriguez, president and CEO, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 at 3:00 PM PT (6:00 PM ET).
The presentation will be available via live webcast and archived recording through Rigel's Investor Relations site at www.rigel.com; investors are advised to connect to the website before the start to allow any required software downloads.
Rigel (Nasdaq: RIGL) presented updated Phase 1b data for R289, an oral prodrug of R835, in relapsed/refractory lower-risk MDS at ASH on December 7, 2025.
Key results as of October 28, 2025: 33 patients (median age 75, median 3 prior therapies) were treated; at doses ≥500 mg QD 6/18 (33%) transfusion-dependent patients achieved durable RBC-TI (>8 weeks), with median time to RBC-TI 1.9 months and median duration 22.9 weeks. R289 was generally well tolerated; common Grade 1/2 AEs included diarrhea (30%) and fatigue (27%). One DLT occurred at 750 mg.
Rigel (Nasdaq: RIGL) will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 8:30 am ET. Dean Schorno, chief financial officer, will deliver the presentation.
Investors can access a live webcast and archived recording via the Investor Relations section of Rigel's website at www.rigel.com; attendees are advised to connect to the site before the start time to allow for any software downloads.
Rigel (NASDAQ: RIGL) published final five-year results from the Phase 2 pivotal cohort of REZLIDHIA (olutasidenib) in relapsed/refractory mIDH1 acute myeloid leukemia in Journal of Hematology & Oncology on Nov 17, 2025. Key five-year findings: CR/CRh 35% (n=147) with median duration 25.3 months, ORR 48% with median duration 15.5 months, and overall median OS 11.5 months. Safety remained consistent with no new signals or new cases of differentiation syndrome reported.
Subgroup: patients with 1–2 prior regimens showed higher response rates and longer OS versus ≥3 prior regimens; 12 patients R/R to venetoclax had 33% CR/CRh and median OS 16.2 months.
Rigel Pharmaceuticals (Nasdaq: RIGL) will present a company overview at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 10:00 a.m. GMT (5:00 a.m. ET).
The presentation will be delivered by Raul Rodriguez, president and CEO, and will be available via live webcast and as an archived recording on the company's Investor Relations website at www.rigel.com. Attendees are advised to connect to the website before the webcast to allow any necessary software downloads.
Rigel (Nasdaq: RIGL) reported Q3 2025 total revenue of $69.5M, including record net product sales of $64.1M (+65% YoY), and net income of $27.9M for the quarter. Year-to-date revenue was $224.5M. Cash, cash equivalents and short-term investments totaled $137.1M as of September 30, 2025.
The company completed dose escalation and began dose expansion in its Phase 1b R289 IRAK1/4 program and will present updated R289 data at ASH in December. Rigel raised 2025 revenue guidance to $285–$290M, including net product sales of $225–$230M, and expects positive net income for full-year 2025.
Rigel (Nasdaq: RIGL) will present updated clinical data at the 67th ASH Annual Meeting, Dec 6-9, 2025, in Orlando and virtually.
An oral presentation (Dec 7) will report updated Phase 1b safety and efficacy for R289 in relapsed/refractory lower‑risk MDS: dose range 250 mg QD to 500 mg BID, 33 patients enrolled (data cutoff Jul 15, 2025), median age 75, 61% high transfusion burden. At ≥500 mg QD evaluable transfusion‑dependent patients, 4/13 (31%) achieved durable RBC‑TI (>8 weeks); median time to RBC‑TI 2.2 months and median duration 24.3 weeks.
Four posters (Dec 6–8) report REZLIDHIA (olutasidenib) data in R/R mIDH1 AML, including late responses after stable disease, real‑world post‑venetoclax outcomes, hematologic improvement timing, and outcomes after prior intensive chemotherapy.
Rigel (Nasdaq: RIGL) will report third quarter 2025 financial results after market close on Tuesday, November 4, 2025. Senior management will host a live conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss results and provide a business update. Participants can join via domestic dial-in 877-407-3088 or international 201-389-0927, and the webcast (with slides) will be available on the company Investor Relations website at www.rigel.com.
The webcast will be archived for 90 days after the call. Rigel is a biotechnology company focused on therapies for hematologic disorders and cancer, headquartered in South San Francisco.
Rigel (Nasdaq: RIGL) announced the first patient has been enrolled in the dose expansion phase of its open-label Phase 1b study of R289 in transfusion dependent relapsed/refractory lower-risk myelodysplastic syndrome (MDS) on Oct 8, 2025. The dose expansion will randomize up to 40 patients to 500 mg once daily or 500 mg twice daily to determine the recommended Phase 2 dose (RP2D).
Enrollment in the dose escalation phase completed in July 2025. The company expects to share updated study data later in 2025. R289 has FDA Orphan Drug and Fast Track designations and remains investigational and not FDA approved.
FAQ
What is the current stock price of Rigel Pharmaceuticals (RIGL)?
What is the market cap of Rigel Pharmaceuticals (RIGL)?
